Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Amgen | INDUSTRY |
| Baylor Scott and White Health | OTHER |
| Kaiser Permanente | OTHER |
| Vanderbilt University Medical Center |
Not provided
Not provided
Not provided
This multi-site study will test whether an opportunistic AI-based CAC screening and notification intervention can improve cholesterol treatment and lower cholesterol levels in adults. The study uses artificial intelligence to detect calcium buildup in heart arteries (coronary artery calcium or CAC) on chest CT scans that patients have already had for other reasons. The study will focus on adults who either have known atherosclerotic cardiovascular disease (ASCVD) or have significant calcium buildup (a CAC score of 100 or higher), and whose cholesterol is not well controlled.
It will also evaluate how well this approach can be implemented at scale across multiple health systems. The main questions it aims to answer are:
Does notifying patients and their clinicians about incidental CAC increase lipid-lowering therapy(LLT) initiation or intensification?
Does the intervention improve Low-Density Lipoprotein(LDL)-cholesterol control and related lipid testing?
How does the intervention affect downstream care (e.g., clinic visits, cardiology referrals, and cardiac testing)?
Researchers will use an FDA-cleared AI algorithm to quantify CAC on previously performed non-gated chest CT scans and identify eligible participants through the electronic health record. Participants will be randomized to receive CAC notification either right away or after a 6-month delay.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early Notification | Experimental | For participants randomized to notification, the affiliated clinician will receive a message notifying them of the presence of CAC. The notification will include a description of the significance of CAC, provide guideline recommendations, and include a personalized CAC image (as possible). The message will recommend having a risk discussion with the participant. Based on site-level stakeholder feedback, this alert can be retriggered at 2 months for participants who do not have LLT initiation or intensification or LDL-C testing. Participants will also receive a notification. Based on stakeholder input, this notification can be delivered centrally or from individual clinicians. The notification will include a description of the significance of CAC, a personalized image (as possible), and recommend a risk discussion with their clinician. |
|
| Delayed Notification | No Intervention | Participants will have their CT scans interpreted and reported according to standard clinical practice. This may mention the presence of CAC in the official radiology imaging report, per usual practice. Participants will not receive any notification beyond this standard of care during the 6-month study period. The study team will send a similar notification as the early notification arm to the participants after completion of the study's primary endpoint assessment. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AI-Detected CAC Notification and Care Facilitation | Other | After randomization to the early notification arm, the study team will send a standardized notification message to the participant's affiliated clinician. The study team will send a message to the participant after a brief delay. Each site will determine the timing between the initial message to the clinician and the participant based on stakeholder feedback. The notification is about the AI-CAC identified on the participant's previous chest CT. It will provide an overview of AI-CAC, a personalized image of AI-CAC, and a recommended risk discussion with their clinician. These clinicians will also be notified of the findings. For participants randomized to early notification who do not undergo LLT initiation, intensification, or LDL testing within 2 months, the clinician and participant will receive a second message at that time. The participants in the delayed notification arm will receive a similar notification 6 months later. |
| Measure | Description | Time Frame |
|---|---|---|
| Lipid-lowering therapy initiation or intensification (LLTI) |
| 6 months after participant randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Aspirin prescription | Number of new Aspirin or other antiplatelet prescription | 6 months after participant randomization |
| Lipid panel (total cholesterol, HDL-C, LDL-C, triglycerides) ordering | Number of Lipid panel ordering |
Not provided
Inclusion Criteria:
Non-gated chest CT performed within the prior 2 years within the health system
Active health system engagement with an affiliated clinician eligible for notification, defined as ≥1 clinical visit within the prior 2 years AND at least one of the following:
Meets one of the following clinical criteria:
Suboptimal LDL-C control, defined as either: Last LDL-C ≥70 mg/dL in the last 2 years, OR No LDL-C measurement in the last 2 years
Note: Site-level variations and additional refinements may occur based on local stakeholder input and patient population identification.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fatima Rodriguez, MD, MPH | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | United States | ||
| Kaiser Permanente Northern California |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Duke University | OTHER |
| University of California, Los Angeles | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 6 months after participant randomization |
| Lipoprotein(a) test ordering | Number of Lipoprotein(a) test ordering | 6 months after participant randomization |
| Changes of total cholesterol, HDL-C, LDL-C, triglycerides, Lipoprotein(a) levels | This outcome measure the changes of the test levels | 6 months after participant randomization |
| Healthcare resource use |
| Baseline through Month 6 |
| Pleasanton |
| California |
| 94588 |
| United States |
| Stanford University | Stanford | California | 94305 | United States |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| Baylor Scott & White | Dallas | Texas | 95226 | United States |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided